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Abstract
Background Measures of health-related quality of life
(HRQoL), like the Short Form (SF)-36, have been sug-
gested to correlate with inflammatory biomarkers. It is,
however, unclear whether a joint measure of two inflam-
matory biomarkers would bring additional information in
comparison with evaluation of one inflammatory
biomarker.
Objective To evaluate associations between SF-36 and
low-grade inflammation in a Swedish population, with
emphasis on a combined measure of C-reactive protein
(CRP) and interleukin-6 (IL-6) as a proxy for low-grade
inflammation.
Methods In a randomly selected sample of a middle-aged
Swedish general population (n = 905; aged 45–69 years,
50 % women), relations between SF-36 parameters and the
biomarkers were tested. Regression and correlation analy-
ses were adjusted for sex, age, presence of disease, life-
style, and psychological factors.
Results After adjustment for sex and age, HRQoL was
significantly lower in the group with a joint elevation of
CRP and IL-6 in comparison with either the group with no
elevation or the groups showing elevation of one of the two
biomarkers. Also after full adjustments, the combined
measure of elevated CRP and IL-6, with few exceptions,
was associated with significantly lower HRQoL in com-
parison with elevations in one of them, difference ranging
from 4 (Mental Health scale) to 18 scale steps (Role-
Physical scale).
Conclusion This study confirms that there is a relation-
ship between HRQoL and low-grade inflammation. In
particular, SF-36 scores are significantly lower in a group
with joint elevation of IL-6 and CRP, in comparison with
elevation of either one of them.
Keywords Biomarkers  CRP  Health-related quality of
life  Inflammation  Interleukin  Population  SF-36
Introduction
Measures of health-related quality of life (HRQoL) are
increasingly used as patient-reported outcome measures
(PROM) within the health-care system, and the assessment
constitutes a potentially important tool for health-care
improvement. Profound understanding of the relations of
HRQoL to other (health-related) factors is therefore crucial
for the interpretation of HRQoL data. HRQoL measures
can be either generic, measuring general health problems,
or disease-specific, i.e., measuring health issues of impor-
tance for a certain disease or condition. One of the most
commonly used generic measures is the Medical Outcome
Study Short Form-36 (SF-36) questionnaire [1], a multi-
item measure which includes 36 questions in eight different
health dimensions (scales), covering physical, social, and
mental function and well-being.
Several groups have independently shown that low SF-
36 scores are associated with increased mortality risk
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[2–4]. We have previously shown that each of the scales of
the SF-36, in addition to lifestyle factors and the presence
of disease, can be explained to a significant extent by
psychological factors, in a similar way for both men and
women [5].
Advances within the field of psychoneuroimmunology
have led to a detailed knowledge about behavioral–neural–
endocrine–immune system interactions [6]. While psy-
chosocial stress and negative emotions are, themselves,
predictors for illness and mortality [7], they have also been
related to increased levels of inflammatory cytokines, e.g.,
interleukin (IL)-6 [8, 9]. Interleukin-6 (IL-6) is a pleio-
tropic cytokine, affecting several biological processes.
Besides the induction of C-reactive protein (CRP), an
acute-phase protein widely used as a biomarker of
inflammation, IL-6 is also linked to the process of inducing
‘‘sickness behavior,’’ a term given to the process whereby
the cytokines affect sleep, eating behavior, and mood
states, making a person experience feelings of ‘‘sickness,’’
discomfort, and low energy [10], all suggested to be
associated with low self-rated health (SRH) [11].
It has been suggested independently by several groups
that there is an association between HRQoL and inflam-
matory biomarkers. This has been shown for SRH [12–15],
but also for more elaborated instruments: Both the SF-36,
or other generic HRQoL instruments in the same family, as
well as various disease-specific HRQoL instruments have
been used in studies where it has been postulated that the
relation between HRQoL and mortality includes a psy-
choneuroimmunological pathway. However, although there
is some empirical support for the associations between
various HRQoL measures and cytokines, results have been
inconsistent and inconclusive [16–26]. Similarly, incon-
sistent results have also been found regarding the associ-
ation between HRQoL and CRP [26–30]. This may, at least
in part, be explained by the heterogeneity of the patient
groups studied, as well as rather small study populations.
As far as we know, there is only one large-scale study
using a combination of inflammatory biomarkers when
evaluating the association between HRQoL and low-grade
inflammation.
A population-based study of the relation between fatigue
[measured using the vitality scale (VT) of the SF-36
questionnaire] and a joint elevation of CRP and IL-6
showed a greater risk of a low score of the VT scale, than
for elevated levels of CRP or IL-6 separately. The other
scales of the SF-36 were not evaluated in this study [31].
In parallel, low-grade inflammation has been found to
predict mortality in older people, independently of the
presence of disease [32, 33]. Of note, the combination of
elevated levels of both IL-6 and CRP has been found to be
associated with a higher mortality risk than measures based
on either of the biomarkers alone [33].
The aim of the present study was to evaluate associa-
tions between HRQoL and low-grade inflammation in a
Swedish general population. In particular, we aimed to
investigate a combined measure of CRP and IL-6 in
comparison with one biomarker at a time. Our hypothesis
was that a combination of CRP and IL-6 would have




Data were collected between October 2003 and May 2004,
using random sampling (stratified according to the catch-
ment areas of 10 different primary health-care centers, sex,
and age at 5-year intervals) of the population in the county
of O¨stergo¨tland, Sweden. An invitation letter was sent by
post, while signing and returning a reply form provided
informed consent. Participants were enrolled until the
predetermined sample size of 500 women and 500 men
between the ages 45 and 69 was obtained (five 5-year age
groups with 50 women and 50 men in each), and finally
resulted in 505 women and 502 men. This constituted the
basis of the ongoing, prospective Life conditions, Stress,
and Health (LSH) study, with a response rate of 62.5 %
[34]. The LSH study was designed to investigate whether
the relationship between socioeconomic status and coro-
nary heart disease might be mediated through biopsy-
chosocial pathways. Since the primary outcome in this
study is coronary heart disease, the age group 45–69 was
chosen to optimize the number of outcomes. Exclusion
criteria were severe physical or mental disease, or diffi-
culties in understanding the Swedish language. The study
sample was representative of the population in terms of
educational attainment, immigrant status, and employment
rates.
Procedures
As part of the protocol of the LSH study, participants
visited their primary health-care centers, where anthropo-
metric and blood pressure measurements, in addition to
blood, urine, and saliva samples, were obtained. All sam-
ples were collected in a fasting state. Out of the 1007
participants, blood samples were eligible for analysis from
961 participants.
Patients were instructed to reschedule their appointment
if they were currently experiencing any acute infections,
e.g., a common cold. At the visit, information about the
voluntariness of participating in the study was given ver-
bally. In order to ensure standardization of the data
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collection, nurses collecting data at the 10 primary health-
care centers were trained together.
Except for sex and age, all other measures in the present
study were self-reported (from questionnaires).
Measures
HRQoL
The Swedish standard version 1 of SF-36 [1, 35] was used
to measure HRQoL. Items are aggregated into eight multi-
item scales, called Physical Functioning (PF), Role-Phys-
ical (RP), Bodily Pain (BP), General Health (GH), Vitality
(VT), Social Functioning (SF), Role-Emotional (RE), and
Mental Health (MH). Items were transformed and summed
according to the manual of the instrument, to give scores
from 0 to 100 for each scale, with a higher score indicating
a better HRQoL [1, 35].
Biological markers
Plasma levels (EDTA plasma) of IL-6 were measured with
ultrasensitive bead kit technology (Invitrogen Co, Carls-
bad, CA, USA) according to the manufacturer’s instruc-
tions and analyzed on a Luminex 100TM system (Austin,
TX, USA). The lower limit of detection was 1.68 pg/ml
and inter-assay coefficient of variance (CV) of 7.0 %, and
proportion of samples with detectable levels was 40 %.
Samples below the detection levels were given a value that
was a third of the detection limit.
C-reactive protein (CRP) was measured in EDTA
plasma by a highly sensitive latex-enhanced turbidimetric
immunoassay (Roche Diagnostics GmbH, Vienna, Austria)
with a lower detection limit of 0.03 mg/l and CV of 1.7 %.
Detectable levels were found for all samples but one,
which received a value of zero.
Aliquots of plasma (0.5 ml) were stored in -70 Celsius
approximately 40 months before analysis.
Presence of disease
The concept ‘‘Presence of disease’’ included two different
variables. The first variable, ‘‘Medical conditions,’’ was
defined as referring to a participant having at least one of
14 medical conditions. Data in the LSH study on medical
conditions were self-reported using a checklist. Participants
were asked whether they had ever been diagnosed by a
physician with any of the 12 following medical conditions:
myocardial infarction, angina pectoris, stroke, chronic
obstructive pulmonary disease, cancer, asthma/allergy,
dyspepsia/peptic ulcer, kidney disease, celiac disease,
hypertension, hyperlipidemia or diabetes mellitus. An open
question asking about the presence of other medical con-
ditions than the above concluded the checklist. Rheumatic
disease and fibromyalgia were common enough to be
added to our variable ‘‘Medical conditions.’’ Another
aspect of illness important to HRQoL is pain, and the
questionnaire contained a question about the presence of
musculoskeletal pain in the back of the neck and/or in the
back (henceforth referred to only as back pain), constitut-
ing the second variable, ‘‘Back pain.’’
Lifestyle factors
Smoking habits were categorized as being either a smoker
(at least one cigarette a day) or not. Those who had quit
smoking within the last 5 years due to illness were also
included in the smoker category. Hazardous alcohol con-
sumption was defined as drinking C9/14 (women/men)
standard glasses/week (one standard glass = 12 g of
alcohol). Those who had abstained from alcohol due to
illness were also included in this category. Questions about
alcohol consumption were part of a validated Food Fre-
quency Questionnaire [36]. Physical activity was measured
by questions about daily physical activity (four levels) and
planned physical exercise (five levels). Responses were
then combined into four activity levels: regularly active,
occasionally active, seldom active or inactive [37]. For the
present study, occasionally and seldom active were then
merged into one category. Body mass index (BMI) was
used as a measure of weight control and categorized as
\25, 25–30, or[30. Weight and height used for calcu-
lating BMI were measured by the nurses during visits to the
primary health-care centers.
Psychological factors
The questionnaires in the LSH study included a broad
range of instruments measuring psychosocial variables.
Earlier [5] we found that, after adjustment for effects of
age, sex, presence of disease, and lifestyle, the following
two instruments (dimensions) were among those that con-
tributed most strongly to the variation of SF 36 scores, and
therefore they were included in the present study. One
instrument represents psychological risk factors (risk fac-
tors for disease; lower scores being favorable). This is The
Center for Epidemiologic Studies Depression scale (CES-
D) [38], which was developed in the 1970s to capture
depressed moods in epidemiological studies. The other
instrument measures resources (that supposedly protect
against disease; higher scores being favorable). This is
Sense of Coherence (SoC), which reflects the extent to
which one feels one’s own life to be comprehensible,
manageable, and meaningful [39].
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Statistical methods
Prior to analyses, cutoffs were set at[10 mg/l for CRP and
[20 pg/ml for IL-6, to exclude participants with an acute
inflammatory response due to, e.g., ongoing infections
(n = 32 for CRP, n = 17 for IL-6).
Descriptive data include mean (SD; range) and
frequency.
Partial correlation analyses, adjusted for age and sex,
were used to explore the relation between the SF-36 and
the biomarkers, and a Fisher r–z transformation was used to
investigate differences in correlation coefficients between
women and men.
The data set was considered to be large enough to use
linear regression analyses on SF-36 scores [40]. Linear
regressions (adjusted for age and sex) were used to explore
the relation between the SF-36 and the explanatory variables
used in the regression analyses, i.e., inflammatory
biomarkers presence of disease, lifestyle, and psychological
factors. The two biomarkers were evaluated one at a time.
The combined effect of CRP and IL-6 was examined by
creating a composite variable with four categories: low CRP
and low IL-6, high CRP and low IL-6, low CRP and high IL-
6, and high CRP and high IL-6. LowCRPwas defined asCRP
\1 mg/l, and high CRP as[3 mg/l, using the Centers for
Disease Control/American Heart Association (CDC/AHA)
criteria regarding risk assessments for cardiovascular disease
[40]. To define high IL-6 levels in the present study, we used
the same proportion of study participants as found for the
high category of CRP. This corresponds to an IL-6 level of
3.25 pg/ml. As the levels to define high and low levels of the
biomarkers are arbitrary, four altered definitionswere used to
categorize an elevation of the biomarkers, using (a) highest
quartile (CRP[ 2.26 mg/l and IL-6[ 2.58 pg/ml), (b) me-
dian split (CRP[ 0.85 mg/l and IL-6[ 0.56 pg/ml), (c) the
same absolute cutoffs as used in the article by Cho et al.
(CRP[ 1.0 mg/l and IL-6[ 1.5 pg/ml) [31], and (d) the
same absolute cutoffs as used in the article by Harris et al.
[33] (CRP[ 2.78 mg/l and IL-6[ 3.15 pg/ml).
A two-sided probability value of p B 0.05 was consid-
ered as statistically significant. Analyses were performed in
STATA statistical software, release 11.0 (Stata Corpora-
tion, College Station, TX, USA), IBM SPSS for Windows
statistical software, release 21 (IBM Corporation, Armonk,
NY, USA).
Results
Descriptive data regarding the study sample (n = 905) are
given in Table 1. Significant sex differences were seen for
many of the variables in Table 1 (back pain, BMI, alcohol
























Occasionally/seldom active 76 640
Regularly active 19 163
Mean SD Range
Psychological instruments
CES-D, Center for Epidemiologic
Studies Depression scale (possible
range 0–60)
8.8 7.7 0–51




PF, Physical Functioning (possible range
0–100)
84.7 18 0–100
RP, Role-Physical (possible range
0–100)
81.6 34 0–100
BP, Bodily Pain (possible range 0–100) 69.2 26 0–100
GH, General Health (possible range
0–100)
70.5 21 5–100
VT, Vitality (possible range 0–100) 66.6 23 0–100
SF, Social Functioning (possible range
0–100)
87.8 20 0–100
RE, Role-Emotional (possible range
0–100)
86.2 29 0–100




IL-6 (pg/ml) 1.9 2.5 0.56–19.5
CRP (mg/l) 1.7 2.0 0–9.9
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consumption, CRP, and all scales of the SF-36 except the
RE scale). Therefore, correlation analyses between the SF-
36 and the biomarkers were first carried out separately for
women and men. However, the Fischer r–z transformation
did not show any significant differences in the correlation
coefficients for women and men, and separating the anal-
yses by sex did not change the main findings. Hence, fur-
ther analyses were adjusted for sex, but were not performed
separately for women and men.
The results of partial correlations (adjusted for age and
sex) between the scales of the SF-36 and the biomarkers
are shown in Table 2. Significant correlation coefficients
for every scale of the SF-36 were found for IL-6, whereas
CRP showed significant relations for all scales except the
MH scale.
All lifestyle and psychological factors, as well as pres-
ence of disease, were related to HRQoL, as expected
(Table 3). High alcohol consumption had the lowest
coefficients in regard to SF-36, but still significant to five of
the eight scales.
In Table 4, the combined measure of CRP and IL-6 in
relation to SF-36 scale scores is shown. When running
dummy variables of the combined variable adjusted for age
and sex, the group with both elevated CRP and elevated IL-
6 has significantly lower SF-score for all the subscales than
any other group. After full adjustments, scale scores are
consistently significantly lower in 19 out of 24 comparisons
for the group with both elevated CRP and IL-6. In Fig. 1,
the mean scores are shown for each group, along with age-
standardized norm values [41]. The groups with either no
elevation or with elevation of one of the biomarkers have
adjusted mean values that are higher or in the same range
as the norm values, whereas the group with both elevated
CRP and elevated IL-6 is considerably lower.
The smallest differences were seen for the Mental
Health scale (where only one of the three comparisons was
significant), and the most pronounced difference was found
for physical role, where the difference in scale scores to the
other groups was about -17 to -18 scale steps.
Four altered ways to define high vs low levels were used
to out-rule potential spurious findings due to arbitrary
cutoffs. Results were largely unchanged for two of them,
namely using either the highest quartile (CRP[ 2.26 mg/l
and IL-6[ 2.58 pg/ml) or the same absolute cutoffs as
used in the article by Harris et al. [33] (CRP[ 2.78 mg/l
and IL-6[ 3.15 pg/ml). These two approaches for altered
cutoffs had significantly lower SF-36 scores in the group
with elevated levels in both biomarkers, with bodily pain as
only exception (data not shown).
However, for median split (CRP[ 0.85 mg/l and IL-
6[ 0.56 pg/ml) and the same absolute cutoffs as used in
the article by Cho et al. [31] (CRP[ 1.0 mg/l and IL-
6[ 1.5 pg/ml), there were significant differences only for
social function and emotional role function, with non-
significant differences in the other comparisons (data not
shown).
Adjusting for physical activity and BMI either as ordinal
categories or dummy variables had no major impact on any
of the above regressions.
Discussion
In the present study, we found significant negative corre-
lations (after adjustment for age and sex) for all scales of
the SF-36 to plasma levels of IL-6 and CRP (except the
MH scale for CRP). The combined measure of both ele-
vated CRP and IL-6 was associated with markedly lower
SF-scores than the groups with elevation of either one of
them. The significantly lower SF-scores for the group with
subclinical elevations of both CRP and IL-6 remained after
adjustments for medical conditions, lifestyle factors, and
psychological factors.
Our findings corroborate the few earlier population-
based studies using a combined measure of inflammatory
biomarkers rather than looking at biomarkers one by one.
Harris et al. [33] found that in a population of older
nondisabled persons (age 77 ± 3.2 years), there was a 2.6
times greater mortality for the joint elevation of high but
Table 1 continued
% n
Combinations of CRP and IL-6 (n = 534)
Low CRP low IL-6 (CRP\ 1 mg/l, IL-6\ 0.57 pg/ml) 67 355
High CRP low IL-6 (CRP[ 3 mg/l, IL-6\ 0.57 pg/ml) 12 66
Low CRP high IL-6 (CRP\ 1 mg/l, IL-6[ 3.25 pg/ml) 10 52
High CRP high IL-6 (CRP[ 3 mg/l, IL-6[ 3.25 pg/ml) 11 61
Table 2 Partial correlation between the SF-36 and the inflammatory
biomarkers, adjusted for age and sex
SF-36 IL-6 CRP
r p r p
PF, Physical Functioning -0.18 \0.001 -0.15 \0.001
RP, Role-Physical -0.09 0.005 -0.12 \0.001
BP, Bodily Pain -0.10 0.001 -0.12 \0.001
GH, General Health -0.15 \0.001 -0.12 \0.001
VT, Vitality -0.10 0.001 -0.07 0.023
SF, Social Functioning -0.13 \0.001 -0.09 0.005
RE, Role-Emotional -0.13 \0.001 -0.08 0.009
MH, Mental Health -0.12 \0.001 -0.02 0.393
Statistically significant correlations are shown in bold. n = 855–905
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Table 3 SF-36 in relation to potential explanatory variables
Explanatory factors SF-36
PF RP BP GH VT SF RE MH
Medical conditions (y/n) -6.5 -12.5 -8.8 -11.1 -8.7 -6.2 -5.4 -3.6
p \0.001 \0.001 \0.001 \0.001 \0.001 \0.001 0.008 0.002
Back pain (y/n) -10.7 -17.8 -27.1 -14.4 -14.7 -7.1 -6.9 -5.4
p 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001
Smoking (y/n) -7.3 -8.8 -8.2 -6.3 -7.2 -5.8 -9.3 -6.1
p 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001
High alcohol consumption (y/n) -5.4 -9.5 -3.1 -5.1 -4.6 -6.9 -11.2 -3.6
p 0.008 0.015 0.304 0.035 0.076 0.002 0.001 0.069
BMI (three categories) -5.8 -7.0 -5.4 -5.8 -4.3 -3.0 -3.2 -1.1
p 0.001 0.001 0.001 0.001 0.001 0.001 0.020 0.144
Physical activity (three categories) 11.2 9.7 7.6 10.0 8.8 4.2 4.8 2.6
p 0.001 0.001 0.001 0.001 0.001 0.002 0.032 0.042
Sense of coherence 3.5 7.7 4.6 8.2 9.5 6.8 10.9 8.9
p 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001
CES-D -4.7 -10.9 -6.3 -10.0 -13.2 -10.5 -16.5 -12.4
p 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001
Regressions adjusted for age and sex. Beta coefficients expressed as change per category (dichotomy, or three categories for body mass index and
physical activity) or per SD increment in continuous scales (psychological factors). Statistically significant findings are shown in bold.
n = 878–976
SF-36: PF Physical Functioning, RP Role-Physical, BP Bodily Pain, GH General Health, VT Vitality, SF Social Functioning, RE Role-
Emotional, MH Mental Health, CES-D Center for Epidemiologic Studies Depression scale
Table 4 SF-36 for different combinations of CRP and IL-6
SF-36 High CRP low IL-6 (n = 66) Low CRP high IL-6 (n = 61) Low CRP low IL-6 (n = 355) R2 values
Model a Model b Model a Model b Model a Model b Model a Model b
PF 10.7 9.8 10.7 8.1 14.7 9.7 0.12 0.33
p \0.001 \0.001 \0.001 0.005 \0.001 \0.001
RP 14.8 17.1 20.7 18.1 20.0 17.1 0.04 0.20
p 0.015 0.006 0.001 0.004 \0.001 0.001
BP 10.3 5.4 16.2 8.8 17.0 7.9 0.06 0.38
p 0.030 0.200 0.001 0.040 \0.001 0.028
GH 12.1 11.0 15.1 9.4 16.1 9.7 0.07 0.38
p 0.002 0.002 \0.001 0.008 \0.001 0.001
VT 9.1 11.3 12.6 9.9 11.0 6.1 0.09 0.47
p 0.026 0.001 0.002 0.005 0.001 0.035
SF 8.0 8.1 8.5 4.2 11.9 7.0 0.07 0.35
p 0.024 0.013 0.018 0.206 \0.001 0.010
RE 13.9 16.7 11.3 8.0 15.4 11.2 0.03 0.26
p 0.011 0.002 0.040 0.145 0.001 0.014
MH 8.8 8.9 7.1 3.9 8.1 4.2 0.07 0.49
p 0.007 0.001 0.031 0.152 0.002 0.062
Beta coefficients represent differences in SF-36 score for dummy variables in comparison with the group with high CRP and high IL-6 (n = 52).
Model a adjusted for age and sex. Model b adjusted for age, sex, presence of disease, lifestyle factors, and psychological factors. Statistically
significant findings are shown in bold
R2, coefficient of determination, is shown for model a and b for each of the scales in SF-36 are in bold italic
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subclinical CRP ((fourth quartile, C2.78 mg/l) and IL-6
(fourth quartile,[3.19 pg/ml) than for lower than median
values (\1.57 mg/l and 2.08 pg/ml, respectively). Persons
with only high IL-6 also had a higher mortality risk, while
persons with only high CRP did not.
In the Whitehall II study, Cho et al. [31] primarily used
the same approach as we did to find cutoffs for CRP,
namely the CDC/AHA criteria [41]. However, when cate-
gorizing the joint elevation, they used the cutoffs high
CRP C 1 mg/l and high IL-6 C 1.5 pg/ml. Fatigue was
defined as scoring B50 on the VT scale of the SF-36 (28 %
of the study population). Of the respondents with no fatigue
at baseline, 20 % scored B50 at follow-up. Persons with
both high CRP and high IL-6 had significantly higher risk
of developing fatigue than persons with only low values,
while those with only one elevated biomarker did not.
Thus, similar to our study, the joint elevation of CRP and
IL-6 had a stronger association with VT than was the case
for elevation in just one of the biomarkers.
Both Harris et al. [33] and Cho et al. [31] used well-
characterized study populations, allowing them to adjust
for a number of relevant factors, similar to our approach. In
all three studies, the relations remained after the adjust-
ments, implying that there seems to be a biological link
between low-grade inflammation and HRQoL. In particu-
lar, although the studies use in part different methods and
biomarker levels, both Harris et al. [33] and Cho et al. [31]
indicate that neither CRP nor IL-6 alone is a sufficient
measure and that a combined measure of the two is supe-
rior. Our data confirm that subclinical elevation in only one
of these two biomarkers may be cumbersome to evaluate as
there are small differences in comparison with the group
without any elevation, whereas an elevation in both may be
a better marker for sustained elevations in low-grade
inflammation.
There were no major differences between the cutoffs
used based on proportion corresponding to CRP[ 3 mg/l,
highest quartile or categorization used by Harris [33]. This
is to be expected, as all these three arbitrary cutoffs are
close to one another in terms of absolute comparisons. In
contrast, our findings were altered substantially when using
median split or the categorization used by Cho [31]. This is
also to be expected, as both these categorizations include a
high number of participants as ‘‘high’’ although inflam-
mation is relatively low (starting from CRP[ 1 mg/l). We
propose that the proportion having 3 mg/l or higher for
CRP could be used to set the cutoff for IL-6. An absolute
level of IL-6 may be cumbersome to define, due to diffi-
culties in measurements of low concentrations and varia-
tions across methodology used.
It might be argued that the large effect of combining the
two biomarkers is unexpected, since IL-6 is one of the
main inducers to release CRP. Therefore, elevations of
CRP reflect elevations of IL-6 to a substantial extent, and
the correlation between the two should be high. However,
importantly, the kinetics differ between the two biomark-
ers, both in release patterns as well as concentrations in
circulation, where both fluctuates considerably but IL-6 has
a much lower half-life than CRP. In samples from a normal
population, we might speculate that elevations in one of the
two biomarkers to a large extent reflect functional acute-
phase response among certain individuals, whereas eleva-
tions in both may be a more valid measure for a long-
standing subclinical inflammation. Thus, it would be
expected that a combination of the two biomarkers has an
impact on the association with HRQoL, whereas a rise in
just one of them does not.
A potential limitation of the study was that the propor-
tion of samples with detectable plasma levels for IL-6 was
low, which might negatively influence the correlation and
regression analyses. However, IL-6 still showed consistent












PF RP BP GH VT SF RE MH
CRP IL-6 lo lo
CRP IL-6 hi lo
CRP IL-6 lo hi
CRP IL-6 hi hi
norm values
Fig. 1 Mean SF-36 scale scores for different combinations of CRP
and IL-6, adjusted for age, sex, presence of disease, lifestyle factors,
and psychological factors. n = 435–457. SF-36: PF Physical Func-
tioning, RP Role-Physical, BP Bodily Pain, GH General Health, VT
Vitality, SF Social Functioning, RE Role-Emotional, MH Mental
Health. CRP C-reactive protein, IL interleukin. CRP hi = 3–10 mg/l,
CRP lo B 1 mg/l, IL-6 hi = 3.25–20 pg/ml, IL-6 lo B 0.56 pg/ml.
Dashed line represents Swedish norm values standardized to the
gender and age distribution in the study population. Significant
differences in group comparisons in relation to group with elevated
levels of both CRP and IL-6 are marked with a filled circle. The group
with elevated levels of both CRP and IL-6 has significantly lower
mean levels of SF-36 scores than other groups in 19 out of 24
comparisons (all except BP for CRP IL6 hi lo, SF, RE and MH for
CRP IL6 lo hi, and MH for CRP IL-6 lo lo)
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difficulties with the measurement bring limitations to
explore appropriate cutoff levels for IL-6. However, this
limitation does not have an impact on our major finding,
that the combination of the two biomarkers has a stronger
association with HRQoL, than the elevation of either one
of them.
Conclusion
This study demonstrates that there is a relationship between
HRQoL and low-grade inflammation. In particular, the
association is significantly stronger when using a combined
measure of IL-6 and CRP in comparison with elevation of
either one of them.
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